Precompetitive consortia in biomedicine-How are we doing?

Nature Biotechnology

Volumn 31, Issue 11, 2013, Pages 979-985

  Mittleman, Barbara ^a,b   Neil, Garry ^c   Cutcher Gershenfeld, Joel ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Johnson and Johnson ^*

^c JOHNSON AND JOHNSON   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NEW DRUG;

ATTITUDE; BIOMEDICINE; COMMERCIAL PHENOMENA; COMPETITION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROWDSOURCING; DECISION MAKING; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT REGULATION; HUMAN; INFLAMMATORY DISEASE; MERGERS AND ACQUISITIONS; NOTE; PRECOMPETITIVE CONSORTIA; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; REWARD; TRANSLATIONAL RESEARCH;

BIOMEDICAL RESEARCH; COMPETITIVE BEHAVIOR; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 84887475231     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2731     Document Type: Note

References (18)

1. FDA. The beginnings: laboratory and animal studies. Information for Consumers (Drugs) http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143475. htm (2011).
2. Miller, G. Necessity driving leery pharma "open." FiercebiotechIT http://www.fiercebiotechit.com/story/necessity-driving-leery- pharma-open/2011-04-04 (2013).
3. Pollack, A. Drug makers join efforts in research. New York Times (20 September 2012).
4. Cutcher-Gershenfeld, J. & Lawson, C. Valuing the commons: a fundamental challenge across complex systems. (NSF, Washington, DC, 2010).
5. Bunin, B.A. & Ekins, S. Drug Discov. Today 16, 643-645 (2011).
6. Lessl, M., Bryans, J.S., Richards, D. & Asadullah, K. Nat. Rev. Drug Discov. 10, 241-242 (2011).
7. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. J. Health Econ. 22, 151-185 (2003).
8. Toronto International Data Release Workshop Authors. Nature 461, 168-170 (2009).
9. Hunter, J. & Stephens, S. Nat. Rev. Drug Discov. 9, 87-88 (2010).
10. Munos, B. Clin. Pharmacol. Ther. 87, 534-536 (2010).
11. Waitz, I., Townsend, J., Cutcher-Gershenfeld, J., Greitzer, E. & Kerrebrock, J. Aviation and the environment: a national vision statement, goals and recommended actions. http://web.mit.edu/aeroastro/partner/reports/congrept- aviation-envirn.pdf (FAA/NASA, Washington, DC, 2004).
12. Masum, H. & Harris, R. Open source for neglected diseases: magic bullet or mirage? (Results for Development Institute, Washington, DC, 2011).
13. Cutcher-Gershenfeld, J., Mittleman, B., Dickherber, A., Mayrand-Chung, S. & Franks, A. Stakeholder alignment in the Biomarkers Consortium. (NSF-VOSS EAGER 0956472, Washington, DC, 2012).
14. Woelfle, M., Olliaro, P. & Todd, M.H. Nat. Chem. 3, 745-748 (2011).
15. Cutcher-Gershenfeld, J., Barrett, B. & Lawson, C. Building the internal organization to support lateral alignment: a case study of the Office of Environment and Energy, Federal Aviation Administration http://ssrn.com/ abstract=2345248 (MIT, Cambridge, Massachusetts, 2005).
16. Walton, R. & McKersie, R. A Behavioral Theory of Labor Negotiations. (McGraw Hill, New York, 1965).
17. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
18. Wagner, J.A. et al. Clin. Pharmacol. Ther. 86, 619-625 (2009).